Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a pharmacokinetic study of aztreonam-avibactam in hospitalized neonates and infants with suspected or confirmed Gram-negative infection
MOH_2024-07-01_013450Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aztreonam + avibactam in Gram-negative bacterial infection, Intra-abdominal infection (IAI), complicated urinary tract infection (cUTI) and 4 more (2 arms), sponsored by Pfizer. Primary endpoints: Pharmacokinetics of aztreonam-avibactam and Safety and tolerability of aztreonam-avibactam. Planned start May 2024; status: not yet recruiting.
02
Drugs
aztreonam + avibactam
03
Conditions
Gram-negative bacterial infectionIntra-abdominal infection (IAI)complicated urinary tract infection (cUTI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on MOH_2024-07-01_013450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-01_013450.